Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis

Tang, Lili; Feng, Wenzhe; Cheng, Jia-Jun; Gong, Yaqiong

doi:10.1007/s00384-020-03599-7

Cited by 19 publications

(22 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This meant that the data of this previous meta-analysis was absence from one RCT using upper gastrointestinal tract to administer FMT. The other meta-analysis by Tang et al [10] did not differentiate patients with active UC and UC in remission. In order to evaluate the efficacy and safety of FMT in active UC and update the previous systematic reviews, we conducted a systematic review and meta-analysis using only high-quality evidence.…”

Section: Introductionmentioning

confidence: 91%

“…However, the efficacy and safety of FMT for treatment of UC is still controversial. Although there were meta-analyses examining this issue [9,10], one of them by Narula et al [9] did not identify the study by Crothers et al [11] which was available in abstract form. This meant that the data of this previous meta-analysis was absence from one RCT using upper gastrointestinal tract to administer FMT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

Liu

et al. 2021

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Aim. Increasing evidence supports the role of the gut microbiota in the etiology of ulcerative colitis (UC). Fecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection; however, its efficacy in UC is still controversial. A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of FMT for treatment of active UC. Methods. We searched Cochrane, Medline, Web of Science, and Embase from inception to February 2020. Randomized controlled trials (RCTs) recruiting adults with active UC, which compared FMT with controls, were eligible. The primary outcome was combined clinical remission with endoscopic remission/response. Secondary outcomes included clinical remission, endoscopic remission, and serious adverse events. Relative risk (RR) with 95% confidence interval (CI) is reported. Results. Five RCTs with 292 participants were eligible for inclusion. When data were pooled for all patients, FMT was associated with a higher combined clinical remission with endoscopic remission/response; the RR of combined outcome not achieving after FMT vs. control was 0.79 (95% CI 0.70-0.88). FMT delivered via lower gastrointestinal route was superior to upper gastrointestinal route with regard to combined clinical remission with endoscopic remission/response ( RR = 0.79 , 95% CI 0.70-0.89). FMT with pooled donor stool ( RR = 0.69 , 95% CI 0.56-0.85) and higher frequency of administration ( RR = 0.76 , 95% CI 0.62-0.93) may be more effective with regard to clinical remission. There was no statistically significant difference in serious adverse events with FMT compared with controls ( RR = 0.98 , 95% CI 0.93-1.03). Conclusion. FMT shows a promising perspective with comparable safety and favorable clinical efficacy for the treatment of active UC in the short term. However, further larger, more rigorously conducted RCTs of FMT in UC are still needed in order to resolve the controversial questions.

show abstract

Section: Introductionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

Liu

et al. 2021

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…51 Twenty two studies used an aerobic preparation of FMT, 14,40,42,43,[45][46][47][48][49][50]52,53,[55][56][57][58][59][60][61][62][63] one used an anaerobic preparation, 54 and two did not specify. 41,51 Two used a semi-anaerobic preparation of FMT (33,37) in which feces was exposed to some oxygen during the procedure but attempts were made to minimize this; for example, prior to preparation, feces was stored in oxygen-depleted saline solution (36). Five studies used fresh feces, four used frozen feces, and two protocols allowed for use of fresh or frozen feces.…”

Section: Methodological Factors For Fmt Manufacture Processmentioning

confidence: 99%

“…Whilst other reviews have been conducted with respect to safety of FMT for indications other than CDI, these reviews are either not recent, 65 or were restricted to a single indication such as IBS [29][30][31] and IBD. [32][33][34] With respect to efficacy, whilst other reviews have been published for single indications, such as IBS [29][30][31] and IBD, [32][33][34] there have been no holistic reviews looking at all indications other than CDI. As far as the authors of this review are aware, this review also represents the most up to date systematic review and metaanalysis of the safety and efficacy of FMT for IBS.…”

Section: Strengths and Weaknesses Of The Reviewmentioning

confidence: 99%

“…There is also promising preclinical evidence supporting the use of FMT in conditions other than CDI, including Major Depressive Disorder, 25,26 schizophrenia, 27 and cardiometabolic syndrome. 28 While reviews of FMT for specific indications such as IBS [29][30][31] and IBD exist, [32][33][34] to date there have been no comprehensive reviews evaluating and synthesizing the entire body of data for both the efficacy and safety of FMT for all conditions other than CDI. This systematic review and metaanalysis addresses the question of whether FMT is safe and effective at treating health conditions other than CDI in humans.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Essential updates 2020/2021: Colorectal diseases (benign)—Current topics in the surgical and medical treatment of benign colorectal diseases

Shinmoto

Miyamoto

Yoshida

et al. 2022

Annals of Gastroent Surgery

View full text Add to dashboard Cite

The development of new drugs for inflammatory bowel disease (IBD) is remarkable, and treatment strategies using multiple agents and various techniques are required; however, the treatment strategy is likely to be complex. Therefore, appropriate evaluation of traditional surgical treatment strategies and accurate knowledge of the efficacy and limitations of novel treatments are required. Total infectious complications were found to be associated with the use of corticosteroids and anti‐tumor necrosis factor‐α agents, but not with immunomodulators, anti‐integrin agents, and 5‐aminosalicylic acid. Regarding surgical procedures for IBD, conceived anastomosis methods, including Kono‐S for Crohn's disease stenosis, are associated with better outcomes than conventional techniques. Autologous cell transplantation for Crohn's fistulae has been shown to have a favorable outcome. Diverticulitis is increasing and will be treated more frequently in the future. Risk factors for the incidence of diverticulitis and differences in pathogenesis according to right or left side diverticulitis have been reported. Antibiotic therapy may be omitted for uncomplicated diverticulitis. Moreover, regarding surgical procedures, both bowel resection and anastomosis are associated with favorable short‐term outcomes, higher stoma closure rate, and superior medical economy compared to Hartmann's procedure. Risk factors for recurrence after diverticulitis surgery may provide better postoperative follow‐up. In this review, we explore the current topics of colorectal benign diseases, focusing on IBD and diverticulitis, based on clinical trials and meta‐analyses from 2020‐2021. This review consolidates the available knowledge and improves the quality of surgical procedures and perioperative management for IBD and diverticulitis.

show abstract

Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis

Cited by 19 publications

References 53 publications

Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis

Essential updates 2020/2021: Colorectal diseases (benign)—Current topics in the surgical and medical treatment of benign colorectal diseases

Contact Info

Product

Resources

About